T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mondelez International
MDLZ
|
+$841M |
| 2 |
Liberty Global Class C
LBTYK
|
+$752M |
| 3 |
Apple
AAPL
|
+$720M |
| 4 |
Tesla
TSLA
|
+$713M |
| 5 |
NXP Semiconductors
NXPI
|
+$648M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$1.2B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.03B |
| 3 |
Gilead Sciences
GILD
|
+$917M |
| 4 |
Pfizer
PFE
|
+$901M |
| 5 |
Nike
NKE
|
+$872M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.88% |
| 2 | Consumer Discretionary | 14.86% |
| 3 | Financials | 14.2% |
| 4 | Technology | 12.51% |
| 5 | Industrials | 9.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Salesforce
CRM
$162B
| $3.32B | 0.7% |
41,808,944
+575,134
| +1% | +$45.1M |
|
27
Thermo Fisher Scientific
TMO
$222B
| $3.3B | 0.7% |
22,353,168
-1,230,660
| -5% | -$182M |
|
|
FISV
28
Fiserv Inc
FISV
$27.8B
| $2.91B | 0.62% |
53,526,108
-1,930,612
| -3% | -$99.4M |
|
29
Becton Dickinson
BDX
$48.9B
| $2.77B | 0.59% |
16,756,013
+628,450
| +4% | +$100M |
|
|
30
NXP Semiconductors
NXPI
$58.9B
| $2.75B | 0.58% |
35,138,274
+7,556,415
| +27% | +$648M |
|
31
Elevance Health
ELV
$86.2B
| $2.72B | 0.58% |
20,744,816
-3,862,731
| -16% | -$529M |
|
32
AutoZone
AZO
$50.1B
| $2.66B | 0.56% |
3,346,627
-62,443
| -2% | -$48.1M |
|
33
Intercontinental Exchange
ICE
$84.5B
| $2.58B | 0.55% |
50,463,590
-2,831,655
| -5% | -$143M |
|
34
PG&E
PCG
$37.5B
| $2.58B | 0.55% |
40,306,326
+651,970
| +2% | +$39M |
|
|
BNY
35
Bank of New York Mellon
BNY
$108B
| $2.58B | 0.55% |
66,301,855
+4,603,313
| +7% | +$183M |
|
36
Humana
HUM
$46.3B
| $2.49B | 0.53% |
13,867,573
+2,620,906
| +23% | +$466M |
|
|
WBA
37
DELISTED
Walgreens Boots Alliance
WBA
| $2.42B | 0.51% |
29,112,785
+3,776,439
| +15% | +$305M |
|
38
American Airlines Group
AAL
$9.93B
| $2.36B | 0.5% |
83,223,851
-11,066,459
| -12% | -$374M |
|
39
Comcast
CMCSA
$89.4B
| $2.36B | 0.5% |
72,278,516
+6,628,336
| +10% | +$206M |
|
|
ALXN
40
DELISTED
Alexion Pharmaceuticals
ALXN
| $2.31B | 0.49% |
19,743,889
-8,470,497
| -30% | -$1.2B |
|
41
Roper Technologies
ROP
$39.9B
| $2.26B | 0.48% |
13,257,347
-226,244
| -2% | -$39.6M |
|
|
42
Tesla
TSLA
$1.31T
| $2.23B | 0.47% |
157,642,185
+47,088,465
| +43% | +$713M |
|
43
McKesson
MCK
$103B
| $2.15B | 0.46% |
11,529,347
-788,741
| -6% | -$138M |
|
44
Johnson & Johnson
JNJ
$631B
| $2.08B | 0.44% |
17,125,863
-1,031,336
| -6% | -$117M |
|
45
Netflix
NFLX
$318B
| $2.05B | 0.43% |
223,603,300
+49,704,240
| +29% | +$478M |
|
46
Citigroup
C
$227B
| $2.02B | 0.43% |
47,662,498
+3,097,763
| +7% | +$137M |
|
47
Vertex Pharmaceuticals
VRTX
$133B
| $2B | 0.42% |
23,247,863
-1,760,630
| -7% | -$152M |
|
48
Willis Towers Watson
WTW
$31.9B
| $1.99B | 0.42% |
16,043,353
+792,341
| +5% | +$97.8M |
|
49
Stryker
SYK
$133B
| $1.97B | 0.42% |
16,480,861
+655,573
| +4% | +$73.3M |
|
50
Medtronic
MDT
$114B
| $1.91B | 0.4% |
22,002,682
-22,197
| -0.1% | -$1.8M |
|
Similar funds
T. Rowe Price Associates's Q2 2016 Portfolio in Review
As of Q2 2016, T. Rowe Price Associates held 2,596 positions worth $472B, up 0.75% from $468B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
T. Rowe Price Associates's Q2 2016 filing shows 95 new, 1,094 increased, 954 reduced and 84 closed positions. Its largest new stake was American Tower Corporation: 2,223,765 shares worth $246M. The largest sale was Alexion Pharmaceuticals, an estimated $1.2B.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 21% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2016 buy was American Tower Corporation: 2,223,765 shares worth $246M.
- T. Rowe Price Associates added most to Mondelez International in Q2 2016, an estimated $841M increase.
- T. Rowe Price Associates's biggest Q2 2016 reduction was Alexion Pharmaceuticals, cutting an estimated $1.2B.
- T. Rowe Price Associates fully exited BAXALTA INC COM STK (DE) in Q2 2016, selling an estimated $750M.
- T. Rowe Price Associates's ten largest holdings make up 16% of its $472B portfolio in Q2 2016.
- T. Rowe Price Associates opened 95 new positions and closed 84 in Q2 2016.
- T. Rowe Price Associates's portfolio value rose 0.75% quarter-over-quarter to $472B.
Based on T. Rowe Price Associates's 13F filing for Q2 2016, filed 15 Aug 2016.